Ken Londoner: BioSig is a tech platform company

Connecticut company BioSig Tech, began generating revenue from product sales, last November, after winning Food & Drug Administration approval in 2018 to sell its PURE EP system.

The Undiscovered Potential of Bioelectronic Medicine

Bioelectronic Medicine is a new field of medicine that combines neuroscience, molecular biology and bioengineering to delve into the nervous system to treat disease and injury without the use of drugs. Bioelectronic Medicine promises to bring new insights into the diagnosis and treatment of diseases and conditions as varied as cancer, rheumatoid arthritis, inflammatory bowel disease, obesity, diabetes, asthma, paralysis, blindness, bleeding, ischemia, organ transplantation, cardiovascular disease, neurodegenerative diseases, and others.

Bioelectronics is a relatively new branch of healthcare, which, as the name suggests, focuses on the nexus of electronics and biological research. The term can encompass a number of different therapies, but BioSig’s main focus is on creating develop and deliver the advanced signal processing solutions that will unlock the future of bioelectronic medicine, starting with the PURE EP™ System. Namely, this Westport-based medical device company is developing a proprietary biomedical signal-processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace.

“Bioelectronic medicine has the potential to transform healthcare throughout the coming decades, much like we’ve seen with the biotech revolution. But the first order of business for those active in the field is to develop a collective vision for how these technologies can improve lives – a vision that other stakeholders can understand and act on,” says Ken Londoner, founder, CEO, and chairman, BioSig Technologies. Since its founding in 2009, BioSig Technologies has been working hard to lead one of the most innovative and most promising frontiers in healthcare. In order to achieve that, BioSig is now ready to commercialize the company’s first product: the PURE EP™ System. Looking further ahead, BioSig expects to publish trial results, grow internationally, and expand their product pipeline.

In 2018, BioSig received FDA 510(k) clearance for PURE EP™, began market launch, and BioSig was uplisted to the NASDAQ national exchange. BioSig Technologies (BSGM) has a market capitalization of $82.52M. Recently BSGM recorded volume of 210046 shares in most recent trading session as compared to an average volume of 185.63K shares. It shows that the shares were traded in the recent trading session and traders shown interest in BSGM stock.

BioSig Technologies Commitment toward Quality Patient Care

Information technology has made significant contributions to our world, especially in the medical industry. Medical technology has evolved from introducing doctors to new equipment to use inside private practices and hospitals to connecting patients and doctors thousands of miles away through telecommunications. Even more, medical scientists and physicians are constantly conducting research and testing new procedures to help prevent, diagnose, and cure diseases as well as developing new drugs and medicines that can lessen symptoms or treat ailments.

For example, BioSig Technologies, a Connecticut-based medicaltechnology company working on advanced biomedical signal processing technology, has been able to improve fidelity of acquired cardiac signals that may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and related procedures. BioSig’s commitment toward offering higher quality of patient care by introducing innovative technological solutions to medicine, has yield some impressive growth in the medical device sector.

With more and more hospitals and practices using medical technology like mobile devices on the job, physicians can now have access to any type of information they need – from drug information, research and studies, patient history or records, and more – within mere seconds.  

Last November, BioSig had signed a research program deal with Mayo Clinic which consisted of several two-to-three-year projects, focusing on the development of additional advanced features of their first product, the PURE EP system, within the field of electrophysiology. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. 

BioSig’s ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia.

Led by their CEO Ken Londoner, a proven management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE  EPTM System. The technology has been developed to address an unmet need in a large and growing market. BioSig is currently focusing on the development of a proprietary biomedical signal processing platform, engineered to meet excess demand for technology in the electrophysiology (EP) marketplace.

PURE EP™ Simulator Gets a U.S. Patent

On June 06, 2019, BioSig Technologies, Inc., a Westport, Conn.-based company that develops a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that the U.S. Patent & Trademark Office allowed a U.S. patent application covering its electrophysiology simulator. The patent application number 15/103,278 entitled, "Systems and Methods For Evaluation of Electrophysiology Systems" was filed on June 9, 2016.

The BioSig Tech PURE EP System Aims for Arrhythmia Market

After nearly a decade of research and development, BioSig Tech could be poised to break into the nearly $5 billion global electrophysiology market.

In the spring of 2018, the West Los Angeles-based medical device company has filed for federal approval for a medical device that can help doctors target the cells that cause arrhythmias, or irregular heartbeats, which increase the risks of cardiac problems and stroke.

This biomedical device, called PURE EP, aims to cut through the background noise of the operating room and its equipment in order to allow doctors to pinpoint parts of the heart that cause atrial fibrillation and ventricular tachycardia.